U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Metastatic Non-Cutaneous Melanoma

MedGen UID:
277365
•Concept ID:
C1334735
•
Neoplastic Process

Definition

A non-cutaneous melanoma that has spread from its original site of growth to another anatomic site. [from NCI]

Recent clinical studies

Etiology

Clinical features and response to systemic therapy in NRAS-mutant Chinese melanoma patients.
Wang J, Jiang H, Huang F, Li D, Wen X, Ding Q, Ding Y, Zhang X, Li J
J Cancer Res Clin Oncol 2023 Feb;149(2):701-708. Epub 2022 Dec 1 doi: 10.1007/s00432-022-04377-4. PMID: 36454283
Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice.
Tjulandin S, Demidov L, Moiseyenko V, Protsenko S, Semiglazova T, Odintsova S, Zukov R, Lazarev S, Makarova Y, Nechaeva M, Sakaeva D, Andreev A, Tarasova A, Fadeyeva N, Shustova M, Kuryshev I
Eur J Cancer 2021 May;149:222-232. Epub 2021 Apr 17 doi: 10.1016/j.ejca.2021.02.030. PMID: 33872982
Genetically determined risk of keratinocyte carcinoma and risk of other cancers.
Dusingize JC, Olsen CM, An J, Pandeya N, Liyanage UE, Law MH, Neale RE, Ong JS, MacGregor S, Whiteman DC
Int J Epidemiol 2021 Aug 30;50(4):1316-1324. doi: 10.1093/ije/dyaa265. PMID: 33370439
The occurrence of non-melanoma malignant skin lesions and non-cutaneous squamous-cell carcinoma among metastatic melanoma patients: an observational cohort study in Denmark.
Li H, Pedersen L, Nørgaard M, Ulrichsen SP, Thygesen SK, Nelson JJ
BMC Cancer 2016 May 3;16:295. doi: 10.1186/s12885-016-2315-0. PMID: 27141983Free PMC Article
Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma.
Alexander M, Mellor JD, McArthur G, Kee D
Med J Aust 2014 Jul 7;201(1):49-53. doi: 10.5694/mja13.10448. PMID: 24999899

Diagnosis

Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma.
Woo TE, Stukalin I, Ding PQ, Goutam S, Sander M, Ewanchuk B, Cheung WY, Heng DYC, Cheng T
Curr Oncol 2023 Sep 30;30(10):8936-8947. doi: 10.3390/curroncol30100646. PMID: 37887546Free PMC Article
Risk factors, clinical outcomes, and natural history of uveal melanoma: a single-institution analysis.
Delgado-Ramos GM, Thomas F, VanderWalde A, King B, Wilson M, Pallera AM
Med Oncol 2019 Jan 21;36(2):17. doi: 10.1007/s12032-018-1230-4. PMID: 30666496
The occurrence of non-melanoma malignant skin lesions and non-cutaneous squamous-cell carcinoma among metastatic melanoma patients: an observational cohort study in Denmark.
Li H, Pedersen L, Nørgaard M, Ulrichsen SP, Thygesen SK, Nelson JJ
BMC Cancer 2016 May 3;16:295. doi: 10.1186/s12885-016-2315-0. PMID: 27141983Free PMC Article
Jejuno-jejunal invagination due to intestinal melanoma.
Resta G, Anania G, Messina F, de Tullio D, Ferrocci G, Zanzi F, Pellegrini D, Stano R, Cavallesco G, Azzena G, Occhionorelli S
World J Gastroenterol 2007 Jan 14;13(2):310-2. doi: 10.3748/wjg.v13.i2.310. PMID: 17226915Free PMC Article
MSG-1 expression in benign and malignant melanocytic lesions of cutaneous and mucosal epithelium.
Sedghizadeh PP, Williams JD, Allen CM, Prasad ML
Med Sci Monit 2005 Jul;11(7):BR189-94. Epub 2005 Jun 29 PMID: 15990678

Therapy

Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma.
Woo TE, Stukalin I, Ding PQ, Goutam S, Sander M, Ewanchuk B, Cheung WY, Heng DYC, Cheng T
Curr Oncol 2023 Sep 30;30(10):8936-8947. doi: 10.3390/curroncol30100646. PMID: 37887546Free PMC Article
Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice.
Tjulandin S, Demidov L, Moiseyenko V, Protsenko S, Semiglazova T, Odintsova S, Zukov R, Lazarev S, Makarova Y, Nechaeva M, Sakaeva D, Andreev A, Tarasova A, Fadeyeva N, Shustova M, Kuryshev I
Eur J Cancer 2021 May;149:222-232. Epub 2021 Apr 17 doi: 10.1016/j.ejca.2021.02.030. PMID: 33872982
Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma -- a clinical update.
Trinh VA, Joseph J, Hwu WJ
Discov Med 2018 Jan;25(135):31-40. PMID: 29466692
The occurrence of non-melanoma malignant skin lesions and non-cutaneous squamous-cell carcinoma among metastatic melanoma patients: an observational cohort study in Denmark.
Li H, Pedersen L, Nørgaard M, Ulrichsen SP, Thygesen SK, Nelson JJ
BMC Cancer 2016 May 3;16:295. doi: 10.1186/s12885-016-2315-0. PMID: 27141983Free PMC Article
Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma.
Alexander M, Mellor JD, McArthur G, Kee D
Med J Aust 2014 Jul 7;201(1):49-53. doi: 10.5694/mja13.10448. PMID: 24999899

Prognosis

Clinical features and response to systemic therapy in NRAS-mutant Chinese melanoma patients.
Wang J, Jiang H, Huang F, Li D, Wen X, Ding Q, Ding Y, Zhang X, Li J
J Cancer Res Clin Oncol 2023 Feb;149(2):701-708. Epub 2022 Dec 1 doi: 10.1007/s00432-022-04377-4. PMID: 36454283
Genetically determined risk of keratinocyte carcinoma and risk of other cancers.
Dusingize JC, Olsen CM, An J, Pandeya N, Liyanage UE, Law MH, Neale RE, Ong JS, MacGregor S, Whiteman DC
Int J Epidemiol 2021 Aug 30;50(4):1316-1324. doi: 10.1093/ije/dyaa265. PMID: 33370439
Risk factors, clinical outcomes, and natural history of uveal melanoma: a single-institution analysis.
Delgado-Ramos GM, Thomas F, VanderWalde A, King B, Wilson M, Pallera AM
Med Oncol 2019 Jan 21;36(2):17. doi: 10.1007/s12032-018-1230-4. PMID: 30666496
What hope for the future? GNAQ and uveal melanoma.
Sisley K, Doherty R, Cross NA
Br J Ophthalmol 2011 May;95(5):620-3. Epub 2011 Mar 3 doi: 10.1136/bjo.2010.182097. PMID: 21378004
Survival of patients with visceral metastatic melanoma from an occult primary lesion: a retrospective matched cohort study.
Vijuk G, Coates AS
Ann Oncol 1998 Apr;9(4):419-22. doi: 10.1023/a:1008201931959. PMID: 9636833

Clinical prediction guides

Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice.
Tjulandin S, Demidov L, Moiseyenko V, Protsenko S, Semiglazova T, Odintsova S, Zukov R, Lazarev S, Makarova Y, Nechaeva M, Sakaeva D, Andreev A, Tarasova A, Fadeyeva N, Shustova M, Kuryshev I
Eur J Cancer 2021 May;149:222-232. Epub 2021 Apr 17 doi: 10.1016/j.ejca.2021.02.030. PMID: 33872982
Genetically determined risk of keratinocyte carcinoma and risk of other cancers.
Dusingize JC, Olsen CM, An J, Pandeya N, Liyanage UE, Law MH, Neale RE, Ong JS, MacGregor S, Whiteman DC
Int J Epidemiol 2021 Aug 30;50(4):1316-1324. doi: 10.1093/ije/dyaa265. PMID: 33370439
Risk factors, clinical outcomes, and natural history of uveal melanoma: a single-institution analysis.
Delgado-Ramos GM, Thomas F, VanderWalde A, King B, Wilson M, Pallera AM
Med Oncol 2019 Jan 21;36(2):17. doi: 10.1007/s12032-018-1230-4. PMID: 30666496
The occurrence of non-melanoma malignant skin lesions and non-cutaneous squamous-cell carcinoma among metastatic melanoma patients: an observational cohort study in Denmark.
Li H, Pedersen L, Nørgaard M, Ulrichsen SP, Thygesen SK, Nelson JJ
BMC Cancer 2016 May 3;16:295. doi: 10.1186/s12885-016-2315-0. PMID: 27141983Free PMC Article
What hope for the future? GNAQ and uveal melanoma.
Sisley K, Doherty R, Cross NA
Br J Ophthalmol 2011 May;95(5):620-3. Epub 2011 Mar 3 doi: 10.1136/bjo.2010.182097. PMID: 21378004

Supplemental Content

Table of contents

    Practice guidelines

    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...